Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design.
Non-adherence to medication specifications is a major cause for poor outcomes in the therapy of schizophrenia. In situ implantable preparation of aripiprazole, an atypical antipsychotic drug, was intended with the aim to improve the patient compliance and to offer an effective antipsychotic drug therapy. D-optimal mixture design was employed to design and optimize long-acting depot injection of aripiprazole using polylactide-co-glycolide (PLGA) 50:50, 75:25, 85:15, and cholesterol as release rate-retarding material. Desirability technique was used for the optimization of formulation. Predicted optimized formulation was experimentally validated, and it was found that the developed formulation releases the drug for a 14-day time period. The optimized formulation showed that the cholesterol-containing formulation exhibits a better drug release profile. The pharmacokinetic studies confirmed that the developed cholesterol-based depot formulation was capable of releasing the drug for a time period of more than 14 days. The implant formulation was sterilized by gamma radiation and ethylene oxide sterilization method. The D-optimal mixture design was proved to be an efficient technique for the formulation optimization.
Nahata
Tushar
T
Department of Pharmacy, Shri G. S. Institute of Technology and Science, Indore (MP), India.
Saini
T R
TR
D000818:Animals; D014150:Antipsychotic Agents / Q000737:chemistry*; D000068180:Aripiprazole; D002626:Chemistry, Pharmaceutical; D007267:Injections; D019344:Lactic Acid / Q000008:administration & dosage; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000008:administration & dosage; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D015363:Quinolones / Q000008:administration & dosage / Q000737:chemistry*; D051381:Rats; D012107:Research Design; D012995:Solubility; D013242:Sterilization; D013678:Technology, Pharmaceutical
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D000068180:Aripiprazole